BAY-Y-5959

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526903

CAS#: 146136-94-9

Description: BAY-Y-5959 is a calcium channel agonist potentially for the treatment of arrhythmia, heart failure and myocardial.


Price and Availability

Size
Price

Size
Price

Size
Price

BAY-Y-5959 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 526903
Name: BAY-Y-5959
CAS#: 146136-94-9
Chemical Formula: C26H24N4O2
Exact Mass: 424.1899
Molecular Weight: 424.504
Elemental Analysis: C, 73.56; H, 5.70; N, 13.20; O, 7.54


Synonym: BAY-Y-5959; BAY-Y5959; BAY-Y 5959; BAYY-5959; BAYY5959; BAYY 5959.

IUPAC/Chemical Name: isopropyl (R)-2-amino-5-cyano-6-methyl-4-(3-phenylquinolin-5-yl)-1,4-dihydropyridine-3-carboxylate

InChi Key: PHJVBZVDUNTGNR-HSZRJFAPSA-N

InChi Code: InChI=1S/C26H24N4O2/c1-15(2)32-26(31)24-23(21(13-27)16(3)30-25(24)28)19-10-7-11-22-20(19)12-18(14-29-22)17-8-5-4-6-9-17/h4-12,14-15,23,30H,28H2,1-3H3/t23-/m1/s1

SMILES Code: O=C(OC(C)C)C1=C(N)NC(C)=C(C#N)[C@H]1C2=CC=CC(N=C3)=C2C=C3C4=CC=CC=C4


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: de Haan S, Greiser M, Harks E, Blaauw Y, van Hunnik A, Verheule S, Allessie M, Schotten U. AVE0118, blocker of the transient outward current (I(to)) and ultrarapid delayed rectifier current (I(Kur)), fully restores atrial contractility after cardioversion of atrial fibrillation in the goat. Circulation. 2006 Sep 19;114(12):1234-42. Epub 2006 Aug 28. PubMed PMID: 16940189.

2: Takagi G, Asai K, Vatner SF, Kudej RK, Rossi F, Peppas A, Takagi I, Resuello RR, Natividad F, Shen YT, Vatner DE. Gender differences on the effects of aging on cardiac and peripheral adrenergic stimulation in old conscious monkeys. Am J Physiol Heart Circ Physiol. 2003 Aug;285(2):H527-34. PubMed PMID: 12860563.

3: Schotten U, Duytschaever M, Ausma J, Eijsbouts S, Neuberger HR, Allessie M. Electrical and contractile remodeling during the first days of atrial fibrillation go hand in hand. Circulation. 2003 Mar 18;107(10):1433-9. PubMed PMID: 12642366.

4: Cabo C, Schmitt H, Wit AL. New mechanism of antiarrhythmic drug action: increasing L-type calcium current prevents reentrant ventricular tachycardia in the infarcted canine heart. Circulation. 2000 Nov 7;102(19):2417-25. PubMed PMID: 11067798.

5: Pu J, Ruffy F, Boyden PA. Effects of Bay Y5959 on Ca2+ currents and intracellular Ca2+ in cells that have survived in the epicardial border of the infarcted canine heart. J Cardiovasc Pharmacol. 1999 Jun;33(6):929-37. PubMed PMID: 10367597.

6: Asai K, Uechi M, Sato N, Shen W, Meguro T, Mathier MA, Shannon RP, Vatner SF. Lack of desensitization and enhanced efficiency of calcium channel promoter in conscious dogs with heart failure. Am J Physiol. 1998 Dec;275(6 Pt 2):H2219-26. PubMed PMID: 9843822.

7: Uechi M, Asai K, Sato N, Vatner SF. Voltage-dependent calcium channel promoter restores baroreflex sensitivity in conscious dogs with heart failure. Circulation. 1998 Sep 29;98(13):1342-7. PubMed PMID: 9751685.

8: Yi GH, Burkhoff D, Zhang H, Zhu SM, Zwas D, Wang J. Hemodynamic effects of a calcium channel promoter, BAY y 5959, are preserved after chronic administration in ischemic heart failure in conscious dogs. J Pharmacol Exp Ther. 1998 Aug;286(2):760-6. PubMed PMID: 9694931.

9: Todaka K, Wang J, Yi GH, Gu A, Zhu SM, Zhang H, Burkhoff D. Effect of BAY y 5959 on myocardial function and metabolism in normal and failing hearts. Am J Physiol. 1998 May;274(5 Pt 2):H1560-8. PubMed PMID: 9612364.

10: Todaka K, Ogino K, Gu A, Burkhoff D. Effect of ventricular stretch on contractile strength, calcium transient, and cAMP in intact canine hearts. Am J Physiol. 1998 Mar;274(3 Pt 2):H990-1000. PubMed PMID: 9530213.

11: Rousseau MF, Massart PE, van Eyll C, Etienne J, Ahn S, Schaefer HG, Mueck W, Bornemann M, Pouleur H. Dose-related hemodynamic and electrocardiographic effects of the calcium promoter BAY y 5959 in the presence or absence of congestive heart failure. J Am Coll Cardiol. 1997 Dec;30(7):1751-7. PubMed PMID: 9385903.

12: Sato N, Uechi M, Asai K, Patrick T, Kudej RK, Vatner SF. Effects of a novel inotropic agent, BAY y 5959, in conscious dogs: comparison with dobutamine and milrinone. Am J Physiol. 1997 Feb;272(2 Pt 2):H753-9. PubMed PMID: 9124435.

13: Bechem M, Goldmann S, Gross R, Hallermann S, Hebisch S, Hütter J, Rounding HP, Schramm M, Stoltefuss J, Straub A. A new type of Ca-channel modulation by a novel class of 1,4-dihydropyridines. Life Sci. 1997;60(2):107-18. PubMed PMID: 9000116.